Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.38

Cyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.38), versus ($0.12) reported last year.

As of March 31, 2018, cash and cash equivalents totaled $21.7 million, compared to $23.9 million as of December 31, 2017. The decrease of $2.2 million was primarily due to net cash used in operating activities.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance